Phase
Condition
Leukemia
Acute Myeloid Leukemia
Platelet Disorders
Treatment
Interferon
Clinical Study ID
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Aged 18-70 years old (including 18 and 70 years old) with newly diagnosedfavorable-risk AML (2022 ELN risk group classification).
Achieved CR1 after 1-2 cycles of standard chemotherapy.
Completed 4-6 cycles of consolidation chemotherapy (including at least 2 cycles ofhigh-dose Cytarabine HDAC regimem).
At the end of consolidation treatment, bone marrow examination confirmed in CR1,flow cytometry MRD negative, but molecular MRD genes (RUNX1:: RUNX1T1, NPM1, andCBFb:: MYH11) decreased by > 3 log, but still detectable.
Performance status score of 0-2 (ECOG).
Liver function: ALT and AST ≤ 2.5 times the upper limit of normal, bilirubin ≤ 2times the upper limit of normal.
Kidney function: Creatinine ≤ 1.5 times the upper limit of normal.
Exclusion
Exclusion Criteria:
Acute promyelocytic leukemia (APL).
AML with normal karyotype and bZIP intramolecular mutations in CEBPA.
≥ CR2 status.
Patients strongly demanding transplantation, and with indications fortransplantation but not eligible for transplantation.
Uncontrolled active infection.
Severe organ dysfunction.
Pregnancy.
Unwillingness to undergo interferon treatment.
Previous hyperthyroidism or hypothyroidism.
Participation in other clinical trials within one month.
Study Design
Connect with a study center
Peking University People's Hospital
Beijing, Beijing 100044
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.